HRP20120346T1 - Derivati kinolinona kao parp i tank inhibitori - Google Patents

Derivati kinolinona kao parp i tank inhibitori Download PDF

Info

Publication number
HRP20120346T1
HRP20120346T1 HRP20120346AT HRP20120346T HRP20120346T1 HR P20120346 T1 HRP20120346 T1 HR P20120346T1 HR P20120346A T HRP20120346A T HR P20120346AT HR P20120346 T HRP20120346 T HR P20120346T HR P20120346 T1 HRP20120346 T1 HR P20120346T1
Authority
HR
Croatia
Prior art keywords
6alkyl
formula
hydrogen
methyl
6alkynyl
Prior art date
Application number
HRP20120346AT
Other languages
English (en)
Inventor
Eduardo Vialard Jorge
Ren� Angibaud Patrick
Anne Mevellec Laurence
Meyer Christophe
Jean Edgard Freyne Eddy
No�lle Constance Pilatte Isabelle
Roux Bruno
Th�rese Jeanne Pasquier Elisabeth
Marc Bourdrez Xavier
Denis Adelinet Christophe
Fran�oise Bernadette Marconnet-Decrane Laurence
Anne Macritchie Jacqueline
Edward Stewart Duffy James
Pate Owens Andrew
Storck Pierre-Henri
Sophie Poncelet Virginie
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20120346T1 publication Critical patent/HRP20120346T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Spoj formule (I), njegovi N-oksidni oblici, farmaceutski prihvatljive adicijske soli i stereokemijski izomerni oblici, naznačen time dam je 0, 1 ili 2 i kada m je 0 tada je namjeravana direktna veza; n je 0, 1, 2, 3 ili 4 i kada n je 0 tada je namjeravana direktna veza; X je direktna veza, CR10R11, (C=O)NR8, NR8, O ili C?C; R1 je aril ili Het; pri čemu aril je fenil ili naftalenil; pri čemu Het je tienil, pirolil, pirolinil, oksazolil, tiazolil, imidazolil, pirazolil, izoksazolil, izotiazolil, oksadiazolil, triazolil, tetrazolil, tiadiazolil, furanil, piperidinil, piridinil, piridazinil, pirimidinil, piperazinil, pirazinil, triazinil, indolizinil, azaindolizinil, indolil, indolinil, benzotienil, indazolil, benzoksazolil, benzimidazolil, benzofuranil, benzotiazolil, benzotriazolil, kromanil, purinil, kinolinil, cinolinil, ftalazinil, kinazolinil, kinoksazolinil, naftiridinil ili pteridinil; dva atoma ugljika na arilu ili Het mogu biti premoštena (tj. formiraju bi- ili triciklički dio) sa dvovalentnim radikalom odabranim od????????-O-CH2-CH2-O- (a-1), ????????-CH2-O-CH2-O- (a-2), ????????-O-CH2-CH2- CH2- (a-3), ????????-O-CH2-CH2-NR8- (a-4), ????????-O-CR82-O- (a-5), ????????-O-CH2-CH2- (a-6), ????????-CH2-N-CH2-CH2- (a-7), ????????-(CH2)3- (a-8), ili????????-(CH2)4- (a-9); svaki aril, Het, premošteni aril ili premošteni Het može biti supstituiran sa jednim, dva, tri, četiri ili pet supstituenata koji su svaki nezavisno odabrani od vodika, halo, cijano, nitro, hidroksikarbonila, C1-6alkila, C2-6alkenila, C2-6alkinila, C3-6cikloalkila, aminoC3-6cikloalkila, haloC1-6alkila, trihaloC1-6alkila, C1-6alkilkarbonila, C1-6alkiloksikarbonila, C2-6alkenilkarbonila, oksima, C1-6alkiloksima, amidoksima, -C?C-CH2O-CH3, -C?C-CH2N(CH3)2, -C?C-Si(CH3)3, hidroksiC1-6alkila, hidroksiC2-6alkenila, hidroksiC2-6alkinila, cijanoC1-6alkila, cijanoC2-6alkenila, aminokarbonilC1-6alkila, C1-6alkilsulfonilC1-6alkila, C1-6alkilsulfonilC2-6alkenila, C1-6alkilsulfonilC1-6alkinila, -PO(OC1-6alkil)2, -B(OH)2, -S-CH3, SF5, C1-6alkilsulfonila, -NR8R9, C1-6alkilNR8R9, -OR8, -C1-6alkilOR8, -CONR8R9, piperidinilC1-6alkila, piperazinilC1-6alkila, C1-6alkilpiperazinilC1-6alkila, morfolinilC1-6alkila, piperidinila, piperazinila, C1-6alkilpiperazinila, morfolinila, fenila, tienila, pirazolila, pirolila, pirolidinila, piridinila, pirimidinila, oksadiazolila, imidazolila, imidazolilC2-6alkinila, C1-6alkilimidazolilC2-6alkinila, cijanopiridinila, fenilC1-6alkila, fenilC2-6alkenila, morfolinilC1-6alkila, C1-6alkiloksifenila, trihaloC1-6alkilfenila, metilpirazolila, halopirimidinila ili dimetilaminopirolidinila; R2 je vodik, metil, etil, propil, C3-6cikloalkil, C3-6cikloalkilmetil, fluor, fenil, cijanofenil ili trifluorometil; R3 je metil, etil, propil, hidroksimetil, halo, trifluorometil, metiloksi ili C1-6alkilkarbonil; R4 je vodik, halo, metil, aminokarbonil, hidroksiaminokarbonil, NR8R9C1-6alkil-, cijanometil, hidroksimetil ili Het; svaki R5, R6 i R7 je neovisno oda

Claims (15)

1. Spoj formule (I), [image] njegovi N-oksidni oblici, farmaceutski prihvatljive adicijske soli i stereokemijski izomerni oblici, naznačen time da m je 0, 1 ili 2 i kada m je 0 tada je namjeravana direktna veza; n je 0, 1, 2, 3 ili 4 i kada n je 0 tada je namjeravana direktna veza; X je direktna veza, CR10R11, (C=O)NR8, NR8, O ili C≡C; R1 je aril ili Het; pri čemu aril je fenil ili naftalenil; pri čemu Het je tienil, pirolil, pirolinil, oksazolil, tiazolil, imidazolil, pirazolil, izoksazolil, izotiazolil, oksadiazolil, triazolil, tetrazolil, tiadiazolil, furanil, piperidinil, piridinil, piridazinil, pirimidinil, piperazinil, pirazinil, triazinil, indolizinil, azaindolizinil, indolil, indolinil, benzotienil, indazolil, benzoksazolil, benzimidazolil, benzofuranil, benzotiazolil, benzotriazolil, kromanil, purinil, kinolinil, cinolinil, ftalazinil, kinazolinil, kinoksazolinil, naftiridinil ili pteridinil; dva atoma ugljika na arilu ili Het mogu biti premoštena (tj. formiraju bi- ili triciklički dio) sa dvovalentnim radikalom odabranim od         -O-CH2-CH2-O- (a-1),         -CH2-O-CH2-O- (a-2),         -O-CH2-CH2- CH2- (a-3),         -O-CH2-CH2-NR8- (a-4),         -O-CR82-O- (a-5),         -O-CH2-CH2- (a-6),         -CH2-N-CH2-CH2- (a-7),         -(CH2)3- (a-8), ili         -(CH2)4- (a-9); svaki aril, Het, premošteni aril ili premošteni Het može biti supstituiran sa jednim, dva, tri, četiri ili pet supstituenata koji su svaki nezavisno odabrani od vodika, halo, cijano, nitro, hidroksikarbonila, C1-6alkila, C2-6alkenila, C2-6alkinila, C3-6cikloalkila, aminoC3-6cikloalkila, haloC1-6alkila, trihaloC1-6alkila, C1-6alkilkarbonila, C1-6alkiloksikarbonila, C2-6alkenilkarbonila, oksima, C1-6alkiloksima, amidoksima, -C≡C-CH2O-CH3, -C≡C-CH2N(CH3)2, -C≡C-Si(CH3)3, hidroksiC1-6alkila, hidroksiC2-6alkenila, hidroksiC2-6alkinila, cijanoC1-6alkila, cijanoC2-6alkenila, aminokarbonilC1-6alkila, C1-6alkilsulfonilC1-6alkila, C1-6alkilsulfonilC2-6alkenila, C1-6alkilsulfonilC1-6alkinila, -PO(OC1-6alkil)2, -B(OH)2, -S-CH3, SF5, C1-6alkilsulfonila, -NR8R9, C1-6alkilNR8R9, -OR8, -C1-6alkilOR8, -CONR8R9, piperidinilC1-6alkila, piperazinilC1-6alkila, C1-6alkilpiperazinilC1-6alkila, morfolinilC1-6alkila, piperidinila, piperazinila, C1-6alkilpiperazinila, morfolinila, fenila, tienila, pirazolila, pirolila, pirolidinila, piridinila, pirimidinila, oksadiazolila, imidazolila, imidazolilC2-6alkinila, C1-6alkilimidazolilC2-6alkinila, cijanopiridinila, fenilC1-6alkila, fenilC2-6alkenila, morfolinilC1-6alkila, C1-6alkiloksifenila, trihaloC1-6alkilfenila, metilpirazolila, halopirimidinila ili dimetilaminopirolidinila; R2 je vodik, metil, etil, propil, C3-6cikloalkil, C3-6cikloalkilmetil, fluor, fenil, cijanofenil ili trifluorometil; R3 je metil, etil, propil, hidroksimetil, halo, trifluorometil, metiloksi ili C1-6alkilkarbonil; R4 je vodik, halo, metil, aminokarbonil, hidroksiaminokarbonil, NR8R9C1-6alkil-, cijanometil, hidroksimetil ili Het; svaki R5, R6 i R7 je neovisno odabran od vodika, halo, C1-6alkiloksi, cijano, C1-6alkila, -OCH2CH2NR8R9, -CH2OCH2CH2NR8R9, -OCH2CH2CH2NR8R9 ili C1-6alkiloksiC1-6alkiloksi; svaki R8 i R9 je neovisno odabran od vodika, halo, C1-6alkila, C2-6alkenila, C2-6alkinila, karbonila, C1-6alkilsulfonilC1-6alkila, C1-6alkiloksiC1-6alkil, hidroksiC1-6alkila, dihidroksiC1-6alkila, cijanoC1-6alkila, trihaloC1-6alkila, fenilC1-6alkila, (diC1-6alkil)aminoC1-6alkila, C1-6alkilsulfonila, morfolinilC1-6alkila, morfolinilkarbonila, piperazinilC1-6alkila, C1-6alkilpiperazinilC1-6alkila, piperidinilC1-6alkila, tiomorfolinilC1-6alkila, C3-6cikloalkilmetila, piridinila, pirimidinila, fenila, halofenila, oksanilC1-6alkila, C1-6alkilsulfonilC1-6alkila ili C1-6alkilkarbonilaminoC1-6alkila; svaki R10 i R11 je neovisno odabran od vodika, metila, hidroksila, ili uzeti zajedno sa atomom ugljika na koji su spojeni mogu formirati ciklopropilni prsten ili radikal formule C(=O).
2. Spoj formule (I) prema zahtjevu 1 naznačen time da m je 0; X je CR10R11 i tada n je 0; ili X je O i tada n je 2; Het je tienil, oksazolil, tiazolil, oksadiazolil, triazolil, tiadiazolil, furanil, piridinil, pirimidinil, azaindolizinil, indazolil, benzoksazolil, benzofuranil, benzotiazolil, benzotriazolil, kinolinil ili kinoksazolinil; dva atoma ugljika na arilu ili Het mogu biti premoštena sa dvovalentnim radikalom odabranim od (a-1), (a-2), (a-4) ili (a-5); svaki aril ili Het ili premošteni aril može biti supstituiran sa jednim, dva, tri, četiri ili pet supstituenata koji su svaki nezavisno odabrani od vodika, halo, cijano, nitro, amino, hidroksikarbonila, C1-6alkila, haloC1-6alkila, trihaloC1-6alkila, C1-6alkilkarbonila, C1-6alkiloksikarbonila, C2-6alkinila, -CH=CH-CN, hidroksiC1-6alkila, cijanoC1-6alkila, -PO(OC1-6alkil)2, -S-CH3, C1-6alkilsulfonila, -NR8R9, -CH2NR8R9, -OR8, -CH2OR8, -CONR8R9, morfolinilC1-6alkila, piperidinila, piperazinila, C1-6alkilpiperazinila, morfolinila, fenila, C1-6alkiloksifenila, pirazolila, metilpirazolila ili oksadiazolila; R2 je metil, etil, propil, C3-6cikloalkil, C3-6cikloalkilmetil, fenil ili cijanofenil; R3 je metil, etil ili hidroksimetil; R4 je vodik; svaki R5, R6 i R7 je vodik; ili svaki R8 i R9 je neovisno odabran od vodika, C1-6alkila, C1-6alkiloksiC1-6alkila, dihidroksiC1-6alkila, cijanoC1-6alkila, trihaloC1-6alkila, fenilC1-6alkila, C1-6alkilsulfonila, morfolinilC1-6alkila, morfolinilkarbonila, piperazinilC1-6alkila ili C1-6alkilpiperazinilC1-6alkila.
3. Spoj formule (I) prema zahtjevu 1 naznačen time da Het je tienil, tiazolil, imidazolil, oksadiazolil, triazolil, tiadiazolil, furanil, piperidinil, piridinil, pirimidinil, piperazinil, azaindolizinil, indolil, indolinil, benzotienil, indazolil, benzoksazolil, benzimidazolil, benzofuranil, benzotiazolil, benzotriazolil, kinolinil, cinolinil ili kinoksazolinil; svaki aril, Het, premošteni aril ili premošteni Het može biti supstituiran sa jednim, dva, tri, četiri ili pet supstituenata koji su svaki nezavisno odabrani od vodika, halo, cijano, nitro, hidroksikarbonila, C1-6alkila, C2-6alkenila, C2-6alkinila, aminoC3-6cikloalkila, trihaloC1-6alkila, C1-6alkilkarbonila, C1-6alkiloksikarbonila, oksima, C1-6alkiloksima, amidoksima, -C≡C-CH2O-CH3, -C≡C-CH2N(CH3)2, -C≡C-Si(CH3)3, hidroksiC2-6alkenila, hidroksiC2-6alkinila, cijanoC1-6alkila, cijanoC2-6alkenila, C1-6alkilsulfonilC1-6alkila, C1-6alkilsulfonilC2-6alkenila, -PO(OC1-6alkil)2, -S-CH3, SF5, C1-6alkilsulfonila, -NR8R9, C1-6alkilNR8R9, -OR8, -C1-6alkilOR8, -CONR8R9, C1-6alkilpiperazinilC1-6alkila, piperidinila, piperazinila, C1-6alkilpiperazinila, morfolinila, fenila, pirolila, pirolidinila, piridinila, oksadiazolila, C1-6alkilimidazolilC2-6alkinila, cijanopiridinila, fenilC2-6alkenila, morfolinilC1-6alkila, C1-6alkiloksifenila, trihaloC1-6alkilfenila, metilpirazolila, halopirimidinila ili dimetilaminopirolidinila; R2 je metil, etil, propil, C3-6cikloalkil, C3-6cikloalkilmetil, fluor, fenil ili cijanofenil; R3 je metil, etil, propil, hidroksimetil, metiloksi ili C1-6alkilkarbonil; R4 je vodik, halo ili metil; svaki R5, R6 i R7 je neovisno odabran od vodika, halo, C1-6alkiloksi, C1-6alkila ili C1-6alkiloksiC1-6alkiloksi; svaki R8 i R9 je neovisno odabran od vodika, C1-6alkila, C2-6alkinila, C1-6alkiloksiC1-6alkila, hidroksiC1-6alkila, dihidroksiC1-6alkila, cijanoC1-6alkila, trihaloC1-6alkila, fenilC1-6alkila, C1-6alkilsulfonila, morfolinilC1-6alkil, morfolinilkarbonila, piperazinilC1-6alkila, C1-6alkilpiperazinilC1-6alkila, C3-6cikloalkilmetila, piridinila, pirimidinila, fenila, halofenila, oksanilC1-6alkila ili C1-6alkilsulfonilC1-6alkila; ili svaki R10 i R11 je neovisno odabran od vodika ili metila.
4. Spoj formule (I) prema bilo kojem od zahtjeva 1 do 3 naznačen time da m je 0 ili I; n je 0 ili 1; X je direktna veza, CR10R11 ili NR8; R1 je fenil, tiadiazolil, piridinil ili pirimidinil; R1 je fenil i je premošten sa dvovalentnim radikalom odabranim od (a-3) ili (a-8); svaki fenil, premošteni fenil, tiadiazolil, piridinil ili pirimidinil može biti supstituiran sa jednim ili dva supstituenta koji su svaki neovisno odabrani od vodika, halo, cijano, C1-6alkila, C2-6alkinila, hidroksiC2-6alkenila ili -OR8; R2 je metil; R3 je metil ili etil; R4 je vodik; svaki R5, R6 i R7 je vodik; svaki R8 je neovisno odabran od vodika ili C1-6alkila i svaki R10 i R11 je vodik.
5. Spoj formule (I) prema bilo kojem od zahtjeva 1, 3 i 4 naznačen time da spoj je Spoj br. 34, Spoj br. 36, Spoj br. 42, Spoj br. 43, Spoj br. 3, Spoj br. 51, Spoj br. 53, Spoj br. 46, Spoj br. 381, Spoj br. 242, Spoj br. 246, Spoj br. 183, Spoj br. 253, Spoj br. 207, Spoj br. 232, Spoj br. 204, Spoj br. 174 ili Spoj br. 252. [image]
6. Spoj formule (I) prema bilo kojem od zahtjeva 1 do 5 naznačen time da je za uporabu kao lijek.
7. Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljive nosače i kao aktivni sastojak terapeutski učinkovitu količinu spoja formule (I) prema bilo kojem od zahtjeva 1 do 5.
8. Uporaba spoja prema bilo kojem od zahtjeva 1 do 5 naznačena time da je za proizvodnju lijeka za liječenje oštećenja tkiva koje proizlazi iz oštećenja stanice ili smrti zbog nekroze ili apoptoze, za liječenje oštećenja živčanog tkiva nastalih zbog ishemije i reperfuzijske ozljede, neuroloških poremećaja i neurodegenerativnih bolesti, za liječenje krvožilnog infarkta; za liječenje kardiovaskularnih bolesti, za liječenje mišićne degeneracije povezane sa starenjem, AIDS-a, imunoloških bolesti povezanih sa starenjem, upale, gihta, artritisa, ateroskleroza, kaheksije, raka, degenerativnih bolesti skeletnih mišića koje uključuju replikativno starenje, dijabetes, traumu glave, poremećaje ulceroznog kolitisa, mišićnu distrofiju, osteoartritis, osteoporozu, kroničnu i/ili akutnu bol, zatajenje bubrega, ishemiju mrežnice, septički šok, te starenje kože; za produljivanje trajanja života i proliferativnog kapaciteta stanica; za promjenu ekspresije gena starih stanica; za kemosenzitiziranje i/ili radiosenzitiziranje tumorskih stanica.
9. Uporaba spoja prema bilo kojem od zahtjeva 1 do 5 naznačena time da je za proizvodnju lijeka za liječenje raka.
10. Uporaba prema zahtjevu 8 i zahtjevu 9 naznačena time da liječenje uključuje kemosenzitiziranje.
11. Uporaba prema zahtjevima 8 i 9 naznačena time da liječenje uključuje radiosenzitiziranje.
12. Kombinirani spoj prema bilo kojem od zahtjeva 1 do 5 naznačen time da je kombinirana sa kemoterapeutskim sredstvom ili antitumorskim sredstvom.
13. Postupak za dobivanje spoja formule (I) prema zahtjevu 1, naznačen time da sadrži a) reakciju intermedijera formule (II) sa odgovarajućim reagensom u reakcijski-inertnom otapalu uz dobivanje spoja formule (I) [image] b) reakciju intermedijera formule (V-a) uz dodavanje suviška baze, u prisutnosti intermedijera formule (VI), pri čemu Halo je kloro ili bromo, u pogodnom otapalu. [image]
14. Spoj formule (II) [image] njegovi N-oksidni oblici, farmaceutski prihvatljive adicijske soli i stereokemijski izomerni oblici, naznačen time da m je 0, 1 ili 2 i kada n je 0 tada je namjeravana direktna veza; n je 0, 1, 2, 3 ili 4 i kada n je 0 tada je namjeravana direktna veza; X je direktna veza, CR10R11, (C=O)NR8, NR8, O ili C≡C; R1 je aril ili Het; pri čemu aril je fenil ili naftalenil; pri čemu Het je tienil, pirolil, pirolinil, oksazolil, tiazolil, imidazolil, pirazolil, izoksazolil, izotiazolil, oksadiazolil, triazolil, tetrazolil, tiadiazolil, furanil, piperidinil, piridinil, piridazinil, pirimidinil, piperazinil, pirazinil, triazinil, indolizinil, azaindolizinil, indolil, indolinil, benzotienil, indazolil, benzoksazolil, benzimidazolil, benzofuranil, benzotiazolil, benzotriazolil, kromanil, purinil, kinolinil, cinolinil, ftalazinil, kinazolinil, kinoksazolinil, naftiridinil ili pteridinil; dva atoma ugljika na arilu ili Het mogu biti premoštena (tj. formiraju bi- ili triciklički dio) sa dvovalentnim radikalom odabranim od         -O-CH2-CH2-O- (a-1),         -CH2-O-CH2-O- (a-2),         -O-CH2-CH2- CH2- (a-3),         -O-CH2-CH2-NR8- (a-4),         -O-CR82-O- (a-5),         -O-CH2-CH2- (a-6),         -CH2-N-CH2-CH2- (a-7),         -(CH2)3- (a-8), ili         -(CH2)4- (a-9); svaki aril, Het, premošteni aril ili premošteni Het može biti supstituiran sa jednim, dva, tri, četiri ili pet supstituenata koji su svaki nezavisno odabrani od vodika, halo, cijano, nitro, hidroksikarbonila, C1-6alkila, C2-6alkenila, C2-6alkinila, C3-6cikloalkila, aminoC3-6cikloalkila, haloC1-6alkila, trihaloC1-6alkila, C1-6alkilkarbonila, C1-6alkiloksikarbonila, C2-6alkenilkarbonila, oksima, C1-6alkiloksima, amidoksima, -C≡C-CH2O-CH3, -C≡C-CH2N(CH3)2, -C≡C-Si(CH3)3, hidroksiC1-6alkila, hidroksiC2-6alkenila, hidroksiC2-6alkinila, cijanoC1-6alkila, cijanoC2-6alkenila, aminokarbonilC1-6alkila, C1-6alkilsulfonilC1-6alkila, C1-6alkilsulfonilC2-6alkenila, C1-6alkilsulfonilC1-6alkinila,-PO(OC1-6alkil)2, -B(OH)2, -S-CH3, SF5, C1-6alkilsulfonila, -NR8R9, C1-6alkilNR8R9, -OR8, -C1-6alkilOR8, -CONR8R9, piperidinilC1-6alkila, piperazinilC1-6alkila, C1-6alkilpiperazinilC1-6alkila, morfolinilC1-6alkila, piperidinila, piperazinila, C1-6alkilpiperazinila, morfolinila, fenila, tienila, pirazolila, pirolila, pirolidinila, piridinila, pirimidinila, oksadiazolila, imidazolila, imidazolilC2-6alkinila, C1-6alkilimidazolilC2-6alkinila, cijanopiridinila, fenilC1-6alkila, fenilC2-6alkenila, morfolinilC1-6alkila, C1-6alkiloksifenila, trihaloC1-6alkilfenila, metilpirazolila, halopirimidinila ili dimetilaminopirolidinila; R2 je vodik, metil, etil, propil, C3-6cikloalkil, C3-6cikloalkilmetil, fluor, fenil, cijanofenil ili trifluorometil; R3 je metil, etil, propil, hidroksimetil, halo, trifluorometil, metiloksi ili C1-6alkilkarbonil; R4 je vodik, halo, metil, aminokarbonil, hidroksiaminokarbonil, NR8R9C1-6alkil-, cijanometil, hidroksimetil ili Het; svaki R5, R6 i R7 je neovisno odabran od vodika, halo, C1-6alkiloksi, cijano, C1-6alkila, -OCH2CH2NR8R9, -CH2OCH2CH2NR8R9, -OCH2CH2CH2NR8R9 ili C1-6alkiloksiC1-6alkiloksi; svaki R8 i R9 je neovisno odabran od vodika, halo, C1-6alkila, C2-6alkenila, C2-6alkinila, karbonila, C1-6alkilsulfonilC1-6alkila, C1-6alkiloksiC1-6alkila, hidroksiC1-6alkila, dihidroksiC1-6alkila, cijanoC1-6alkila, trihaloC1-6alkila, fenilC1-6alkila, (diC1-6alkil)aminoC1-6alkila, C1-6alkilsulfonila, morfolinilC1-6alkila, morfolinilkarbonila, piperazinilC1-6alkila, C1-6alkilpiperazinilC1-6alkila, piperidinilC1-6alkila, tiomorfolinilC1-6alkila, C3-6cikloalkilmetila, piridinila, pirimidinila, fenila, halofenila, oksanilC1-6alkila, C1-6alkilsulfonilC1-6alkila ili C1-6alkilkarbonilaminoC1-6alkila; svaki R10 i R11 je neovisno odabran od vodika, metila, hidroksila, ili uzeti zajedno sa atomom ugljika na koji su spojeni mogu formirati ciklopropilni prsten ili radikal formule C(=O).
15. Postupak za dobivanje spoja formule (11) prema zahtjevu 14, naznačen time da sadrži a) konverziju ketonske skupine intermedijera formule (III) u hidroksi skupinu, sa odgovarajućim redukcijskim sredstvom, u pogodnom otapalu, uz formiranje spojeva formule (II), pri čemu R3 je hidroksimetil, koji se ovdje nazivaju intermedijeri formule (II-a), [image] b) dodavanje kalijeve soli 2-metil-2-propanola, u intermedijere formule (V-b) u prisutnosti intermedijera formule (VI), pri čemu Halo je kloro ili bromo, u pogodnom otapalu, uz formiranje spojeva formule (II), pri čemu R3 je metil, etil ili propil i R2 je metil, etil, C3-6cikloalkil ili fenil, koji se ovdje nazivaju intermedijeri formule (II-b), [image] c) dodavanje kalijeve soli 2-metil-2-propanola, u intermedijere formule (VII) u prisutnosti intermedijera formule (VIII), pri čemu Halo je kloro ili bromo, u pogodnom otapalu, uz formiranje spojeva formule (II), pri čemu R3 je metil, etil ili propil i R2 je propil ili C3-6cikloalkilmetil, koji se ovdje nazivaju intermedijeri formule (II-c). [image]
HRP20120346AT 2007-03-08 2012-04-18 Derivati kinolinona kao parp i tank inhibitori HRP20120346T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89368007P 2007-03-08 2007-03-08
EP07103788 2007-03-08
PCT/EP2008/052764 WO2008107478A1 (en) 2007-03-08 2008-03-07 Quinolinone derivatives as parp and tank inhibitors

Publications (1)

Publication Number Publication Date
HRP20120346T1 true HRP20120346T1 (hr) 2012-05-31

Family

ID=38421149

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120346AT HRP20120346T1 (hr) 2007-03-08 2012-04-18 Derivati kinolinona kao parp i tank inhibitori

Country Status (11)

Country Link
US (2) US8299256B2 (hr)
EP (1) EP2134691B1 (hr)
JP (1) JP5545955B2 (hr)
AT (1) ATE542799T1 (hr)
AU (1) AU2008223793B2 (hr)
CA (1) CA2678248C (hr)
DK (1) DK2134691T3 (hr)
ES (1) ES2381446T3 (hr)
HR (1) HRP20120346T1 (hr)
SI (1) SI2134691T1 (hr)
WO (1) WO2008107478A1 (hr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101118582B1 (ko) 2003-11-20 2012-02-27 얀센 파마슈티카 엔.브이. 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
NZ551680A (en) 2004-06-30 2010-02-26 Janssen Pharmaceutica Nv Quinazolinone derivatives as PARP inhibitors
MXPA06014542A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de poli(adp-ribosa) polimerasa-i.
CN101242822B (zh) 2005-07-18 2011-08-24 彼帕科学公司 治疗卵巢癌的药物
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
CN101534836B (zh) 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008107478A1 (en) 2007-03-08 2008-09-12 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
RU2490260C2 (ru) * 2008-03-27 2013-08-20 Янссен Фармацевтика Нв Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
ATE513818T1 (de) * 2008-03-27 2011-07-15 Janssen Pharmaceutica Nv Chinazolinonderivate als tubulinpolymerisationshemmer
JP5439745B2 (ja) * 2008-05-27 2014-03-12 宇部興産株式会社 ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
EP2313093A4 (en) 2008-07-10 2012-03-28 Angion Biomedica Corp METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY
US20110098304A1 (en) * 2008-10-22 2011-04-28 Bijoy Panicker Small molecule inhibitors of PARP activity
NZ608069A (en) 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
CN110711188A (zh) 2012-01-20 2020-01-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
NZ630170A (en) 2012-02-09 2016-03-31 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
CN104169284B (zh) 2012-03-28 2017-03-29 默克专利股份公司 双环吡嗪酮衍生物
JP6097820B2 (ja) * 2012-05-04 2017-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピロロトリアジノン誘導体
CA2881330C (en) 2012-08-08 2020-07-21 Merck Patent Gmbh (aza-)isoquinolinone derivatives
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
EP2900643B1 (en) 2012-09-26 2017-09-27 Merck Patent GmbH Quinazolinone derivatives as parp inhibitors
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2015013581A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
BR112016025396A2 (pt) 2014-05-07 2017-08-15 Merck Patent Gmbh derivados de heterociclil-butanamida
CA2977685C (en) 2015-03-02 2024-02-20 Sinai Health System Homologous recombination factors
DK3356345T3 (da) 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
IL274936B2 (en) 2017-12-13 2023-09-01 Lupin Ltd Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors
AU2019392502A1 (en) 2018-12-03 2021-07-22 Merck Patent Gmbh 4-heteroarylcarbonyl-N-(phenyl or heteroaryl) piperidine-1-carboxamides as inhibitors of tankyrases
CN114026085A (zh) 2019-04-11 2022-02-08 安吉昂生物医药公司 (e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式
CA3145644A1 (en) 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors
WO2022247816A1 (zh) 2021-05-24 2022-12-01 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1006423B (de) 1952-01-18 1957-04-18 Ciba Geigy Verfahren zur Herstellung von Hydrazinophthalazinen
GB732581A (en) 1952-01-18 1955-06-29 Ciba Ltd Manufacture of hydrazine compounds
US3274194A (en) * 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3919425A (en) * 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
BE792206A (hr) 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
US3879393A (en) 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
FR2436781A1 (fr) 1978-09-19 1980-04-18 Berri Balzac Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
ZM1785A1 (en) 1984-03-26 1986-03-27 Janssen Pharmaceutica Nv Anti-virally active phyridazinamines
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US5231184A (en) * 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0391462A1 (en) 1989-04-05 1990-10-10 Janssen Pharmaceutica N.V. Synergistic compositions containing ketanserin
US5160727A (en) 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
IE913473A1 (en) * 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
ATE201677T1 (de) 1992-04-23 2001-06-15 Merrell Pharma Inc 4-imidomethyl-1-(2'-phenyl-2-oxoethyl)-piperidi e als serotonin-5ht2-antagonisten, ihre herstellung und therapeutische anwendung
TW294595B (hr) 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
EP0927192B1 (de) 1996-09-10 2004-05-12 Boehringer Ingelheim Pharma GmbH & Co.KG Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2291630A1 (en) * 1997-05-30 1998-12-03 Tetsutaro Niizato Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6407116B1 (en) 1997-09-16 2002-06-18 Takeda Chemical Industries, Inc. Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
JP2000191659A (ja) 1999-01-04 2000-07-11 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
AU773795B2 (en) 1999-01-29 2004-06-03 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
US7265115B2 (en) * 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
ES2309095T3 (es) 2000-10-02 2008-12-16 Janssen Pharmaceutica Nv Antagonistas de los receptores metabotropicos de glutamato.
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
EP1423120A4 (en) 2001-08-15 2005-12-28 Icos Corp 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CA2479109C (en) 2002-03-29 2011-08-02 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
ATE540928T1 (de) 2002-11-22 2012-01-15 Mitsubishi Tanabe Pharma Corp Isochinolinverbindungen und ihre medizinische verwendung
US20050075364A1 (en) 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
NZ546990A (en) * 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
KR101118582B1 (ko) * 2003-11-20 2012-02-27 얀센 파마슈티카 엔.브이. 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
CN102127056B (zh) 2003-12-03 2013-08-21 Ym生物科学澳大利亚私人有限公司 微管蛋白抑制剂
US7879857B2 (en) * 2003-12-05 2011-02-01 Janssen Pharmaceutica Nv 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors
UA91007C2 (ru) * 2003-12-10 2010-06-25 Янссен Фармацевтика Н.В. Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
CN1988907B (zh) 2004-06-01 2010-12-22 弗吉尼亚大学专利基金会 癌瘤及血管生成的双重小分子抑制剂
MXPA06014542A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de poli(adp-ribosa) polimerasa-i.
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
NZ551680A (en) * 2004-06-30 2010-02-26 Janssen Pharmaceutica Nv Quinazolinone derivatives as PARP inhibitors
AU2006214164B2 (en) 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
WO2006118231A1 (ja) * 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation シアノピリジン誘導体及びその医薬としての用途
BRPI0615096A2 (pt) 2005-08-24 2009-07-14 Inotek Pharmaceuticals Corp análogos de indenoisoquinolinona e métodos de uso dos mesmos
DK1984333T3 (da) 2006-02-03 2012-07-23 Bionomics Ltd Substituerede benzofuraner, benzothiophener, benzoselenophener og indoler og deres anvendelse som inhibitorer af tubulinpolymerisering
EP1989204B1 (en) 2006-02-15 2014-05-21 AbbVie Inc. Pyrazoloquinolones are potent parp inhibitors
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
WO2008107478A1 (en) 2007-03-08 2008-09-12 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
EP2170866B1 (en) * 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use

Also Published As

Publication number Publication date
DK2134691T3 (da) 2012-05-07
WO2008107478A1 (en) 2008-09-12
US20100168065A1 (en) 2010-07-01
WO2008107478A8 (en) 2008-10-23
CA2678248A1 (en) 2008-09-12
JP5545955B2 (ja) 2014-07-09
US8299256B2 (en) 2012-10-30
ES2381446T3 (es) 2012-05-28
AU2008223793A1 (en) 2008-09-12
JP2010520262A (ja) 2010-06-10
AU2008223793B2 (en) 2012-08-23
US8778966B2 (en) 2014-07-15
SI2134691T1 (sl) 2012-06-29
CA2678248C (en) 2016-06-28
EP2134691B1 (en) 2012-01-25
EP2134691A1 (en) 2009-12-23
US20130018017A1 (en) 2013-01-17
ATE542799T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
HRP20120346T1 (hr) Derivati kinolinona kao parp i tank inhibitori
ES2949404T3 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
ES2902806T3 (es) Composiciones que contienen compuestos de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo sustituidos como inhibidores de PDE2
JP6524081B2 (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
ES2795366T3 (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas
ES2901197T3 (es) Moduladores alostéricos de los receptores nicotínicos de la acetilcolina
RU2655914C2 (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP6162144B2 (ja) ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用
CA2829117C (en) Novel 6-arylamino pyridone carboxamide as mek inhibitors
AU2006297124B2 (en) 2-amino-7,8-dihydro-6H-pyrido(4,3-d) pyrimidin-5-ones
HRP20150139T1 (hr) Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina
ES2627788T3 (es) Compuestos heteroarilo y procedimientos de uso de los mismos
CN108699077A (zh) 作为rsv抑制剂的杂环化合物
AU2016322848B2 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
ES2702477T3 (es) Compuestos (hetero) aromáticos bicíclicos fusionados útiles para el tratamiento de cánceres
JP2015533782A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
WO2012151567A1 (en) Pyrimidinone compounds and methods for preventing and treating influenza
HRP20170695T1 (hr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka
WO2008150899A1 (en) Combination therapies for treatment of cancer and inflammatory diseases
KR20050013562A (ko) Ｊａｋ 및 ｃｄｋ2 프로테인 키나아제의 억제제
CA2647036A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
AU2014234908B2 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors
WO2014204263A1 (en) Substituted pyridinone compounds as mek inhibitors
CN103476776A (zh) 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
AU2020295399A1 (en) Small molecule target bromo/acetyl proteins and uses thereof